Trial Outcomes & Findings for Novel Methods for Ascertainment of Gout Flares -A Pilot Study (NCT NCT02855437)
NCT ID: NCT02855437
Last Updated: 2019-10-28
Results Overview
Percentage of total study population preferring IVR vs. RheumPRO
COMPLETED
NA
44 participants
6 months
2019-10-28
Participant Flow
The target population recruited was patients with gout. Patients were recruited from the UAB gout clinic, The Kirklin Clinic, and the UNMC gout clinic.
Participant milestones
| Measure |
Interactive Voice Response, Then RheumPRO
IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
|
RheumPro Smartphone Application, Then IVR
RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm.
|
|---|---|---|
|
Phase 1
STARTED
|
23
|
21
|
|
Phase 1
COMPLETED
|
21
|
19
|
|
Phase 1
NOT COMPLETED
|
2
|
2
|
|
Crossover Period (Same Day)
STARTED
|
21
|
19
|
|
Crossover Period (Same Day)
COMPLETED
|
21
|
19
|
|
Crossover Period (Same Day)
NOT COMPLETED
|
0
|
0
|
|
Phase 2
STARTED
|
21
|
19
|
|
Phase 2
COMPLETED
|
20
|
18
|
|
Phase 2
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
Baseline characteristics by cohort
| Measure |
Overall
n=44 Participants
Overall description of participants in the pilot study entitled, "Novel Methods for Ascertainment of Gout Flares -A Pilot Study"
|
|---|---|
|
Age, Continuous
|
49.3 years
STANDARD_DEVIATION 14.5 • n=99 Participants
|
|
Sex: Female, Male
Female
|
7 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Race · White race
|
30 Participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Race · Black or other race
|
14 Participants
n=99 Participants
|
|
Age of first gout flare
|
38.3 Years
STANDARD_DEVIATION 18.6 • n=99 Participants
|
|
Number of flares prior 6 months
2-3 flares in prior 6 months
|
19 Participants
n=99 Participants
|
|
Number of flares prior 6 months
>=4 flares in prior 6 months
|
25 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: 6 monthsPopulation: Preference of IVR and StudyBuddy for reporting gout flares as reported by participants
Percentage of total study population preferring IVR vs. RheumPRO
Outcome measures
| Measure |
Interactive Voice Response
n=38 Participants
The interactive voice response system (IVR) is an automated telephone system that is used to contact participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
IVR (Phone call): IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack
|
RheumPro Smartphone Application
n=38 Participants
RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
RheumPro (Smartphone application): RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. In addition RheumPro questionnaires at months 1 , 3, and 6 will assess RheumPro ease of use.
|
|---|---|---|
|
Preference IVR vs RheumPRO
|
3 Participants
|
28 Participants
|
PRIMARY outcome
Timeframe: 6 monthsFeasibility ----Assessed by the percentage of participants completing answer IRV/RheumPRO queries.
Outcome measures
| Measure |
Interactive Voice Response
n=38 Participants
The interactive voice response system (IVR) is an automated telephone system that is used to contact participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
IVR (Phone call): IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack
|
RheumPro Smartphone Application
n=38 Participants
RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
RheumPro (Smartphone application): RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled "pop-up" to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more "pop-ups" at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. In addition RheumPro questionnaires at months 1 , 3, and 6 will assess RheumPro ease of use.
|
|---|---|---|
|
Feasibility of Using IVR vs. RheumPRO to Report Gout Flares
|
81 percentage of weekly response
Standard Deviation 21
|
80 percentage of weekly response
Standard Deviation 25
|
Adverse Events
Interactive Voice Response
RheumPro Smartphone Application
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place